Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 3:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 27,150 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia, Schizophreniform Disorder
Interventions
Citalopram, Placebo, Psychoeducation, Cognitive Behavioral Therapy (CBT), Functional Magnetic Resonance Imaging (fMRI)
Drug · Behavioral · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years to 40 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
Acne Vulgaris
Interventions
BTX 1503, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
Little Rock, Arkansas • Encino, California • Murrieta, California + 21 more
Conditions
Major Depression
Interventions
D-Cycloserine (DCS), Continuous theta-burst stimulation (cTBS), Transcranial Magnetic Stimulation Sham, Memantine, Lorazepam (drug), Baclofen, Placebo
Drug · Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Belmont, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age

NCT01206478
Conditions
Chronic Oral Food Refusal
Interventions
Amitriptyline, Placebo, Megestrol
Drug
Lead sponsor
Ann Davis, PhD, MPH, ABPP
Other
Eligibility
9 Months to 8 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
3
States / cities
Kansas City, Kansas • New Orleans, Louisiana • Columbus, Ohio
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, GSK1614235
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
volinanserin, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers

NCT03645408
Conditions
Alcohol Use Disorder
Interventions
Exenatide, Sham injection
Drug · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Improving the Efficacy of Anti-Nicotine Immunotherapy

NCT01280968
Conditions
Nicotine Dependence
Interventions
NIC002 in Aluminum hydroxide (Alum), Placebo Vaccine - Aluminum hydroxide
Biological
Lead sponsor
Alexey Mukhin
Other
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Winston-Salem, North Carolina
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK557296
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
Treatment Resistant Depression
Interventions
Liafensine, Placebo
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
41
States / cities
Huntsville, Alabama • Phoenix, Arizona • Garden Grove, California + 36 more
Conditions
Dental Pain
Interventions
Full Dose Strength, Quarter dose strength, Half dose strength, Acetaminophen standard dose, Ibuprofen low dose, Ibuprofen high dose, Placebo
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
16 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Austin, Texas
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Conditions
Eating Disorders (Excluding Anorexia Nervosa), Binge-Eating Disorder
Interventions
Building Healthy Eating and Self-Esteem Together for University Students, Present-Centered Therapy
Behavioral
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lawrence, Kansas
Conditions
Schizophrenia
Interventions
NW-3509a
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Long Beach, California
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers

NCT02272764
Conditions
Pharmacokinetics
Interventions
Itraconazole, ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Not applicable Interventional Accepts healthy volunteers

The RAMP Study - Rejuvenation of the Aging Microbiota With Prebiotics

NCT03690999
Conditions
Microbiome, Immune Function, Inflammation
Interventions
Placebo, Prebiotic supplement
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Conditions
Healthy
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV), TDV New Formulation, Placebo, New Formulation Placebo
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Fort Collins, Colorado • Galveston, Texas • West Jordan, Utah
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Bifeprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
National City, California
Conditions
Prostatic Neoplasms
Interventions
Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more
Conditions
Diabetes Mellitus, Type II
Interventions
HM-002-1005
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hialeah, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of LLLT/Music for Smoking Cessation

NCT04830384
Conditions
Nicotine Dependence, Cigarettes
Interventions
Fully Active, LLLT Only, Music Only, Placebo
Device
Lead sponsor
Freedom Laser, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Mendham, New Jersey
Conditions
Diabetic Neuropathies
Interventions
Placebo, [S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anniston, Alabama • Birmingham, Alabama • Mission Viejo, California + 24 more
Conditions
Hepatitis C
Interventions
GSK2485852 70 mg, GSK2485852 420 mg, placebo, GSK2485852 630 mg, GSK2485852 70 mg + Ritonavir 100mg, GSK2485852 210 mg +Ritonavir 100mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Anaheim, California • Orlando, Florida • Lenexa, Kansas + 2 more